Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 5/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TK1 | P04183 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21396394 | 0.77 | PNP (0.51) | PNPHPGDALDH1A1HPRT1MAPT | |
| SCHEMBL21396398 | 0.76 | PNP (0.52) | PNPALDH1A1HPRT1MAPTTK1 | |
| SCHEMBL21396401 | 0.75 | PNP (0.42) | PNPHPRT1MAPTTK1HSD17B10 | |
| SCHEMBL21396435 | 0.73 | PNP (0.42) | PNPHPGDALDH1A1MAPK1TK1 | |
| SCHEMBL21396481 | 0.71 | MEN1 (0.44) | PNPHPGDALDH1A1MAPK1MAPT | |
| SCHEMBL5256051 | 0.68 | HPRT1 (0.65) | PNPALDH1A1HPRT1TK1MEN1 | |
| SCHEMBL8437638 | 0.68 | PNP (0.44) | PNPHPGDALDH1A1MAPK1MEN1 | |
| SCHEMBL21396362 | 0.67 | PNP (0.56) | PNPALDH1A1HPRT1TK1MEN1 | |
| SCHEMBL21396414 | 0.67 | PNP (0.47) | PNPMAPTTK1KMT2AHSD17B10 | |
| SCHEMBL456162 | 0.67 | MAPK1 (0.44) | PNPHPGDALDH1A1MAPK1HPRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242568-A1 | POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | MIRECA MEDICINES GMBH (DE) | 2023-08-03 | — | — | US | disclosed |
| US-20210317156-A1 | NEW POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | MIRECA MEDICINES GMBH (DE) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242568-A1 | POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | PRKG1, PRKG2, PRKAG3 | PNP 111/4885PTGDR2 1901/4885HPGD 938/4885 |
| US-20210317156-A1 | NEW POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | PRKG1, PRKG2, PDE7A | PNP 106/4885PTGDR2 1843/4885HPGD 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.